Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.89 |
| ▸ | CA2 | P00918 | 1/20 | 0.89 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 2/20 | 0.52 |
| ▸ | NQO2 | P16083 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.48 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.48 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.48 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL542321 | 1.00 | CA1 (0.89) | CA1CA2CYP1A2PTGS1MGLL | |
| SCHEMBL22931544 | 0.79 | AHR (0.68) | CA1CA2CYP1A2PTGS1NQO2 | |
| SCHEMBL13790263 | 0.79 | AHR (0.68) | CA1CA2CYP1A2PTGS1NQO2 | |
| SCHEMBL13790273 | 0.79 | AHR (0.68) | CA1CA2CYP1A2PTGS1NQO2 | |
| SCHEMBL2909442 | 0.79 | CA1 (0.59) | CA1CA2CYP1A2PTGS1MGLL | |
| SCHEMBL2909444 | 0.79 | CA1 (0.59) | CA1CA2CYP1A2PTGS1MGLL | |
| SCHEMBL2352948 | 0.77 | CA1 (0.57) | CA1CA2MGLLFBP1P4HB | |
| SCHEMBL3317126 | 0.77 | CA1 (0.57) | CA1CA2MGLLFBP1P4HB | |
| SCHEMBL29507308 | 0.77 | AHR (0.65) | CA1CA2CYP1A2PTGS1NQO2 | |
| SCHEMBL13204210 | 0.76 | CA1 (0.61) | CA1CA2PTGS1MGLLORAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | claimed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | disclosed |
| US-12512511-B2 | Solid electrolyte including polymer containing boron and fluorine structure, preparation method, and lithium ion battery including the same | ZHUHAI COSMX BATTERY CO., LTD. (CN) | 2025-12-30 | — | — | US | disclosed |
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | DONG-A ST CO., LTD. (KR) | 2025-09-11 | — | — | US | disclosed |
| EP-4514780-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | Dong-A ST Co., Ltd. (KR) | 2025-03-05 | — | — | EP | disclosed |
| US-20250066365-A1 | Ribonucleoside Analogues Against -Sars-Cov-2 | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-02-27 | — | — | US | disclosed |
| US-12186313-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-01-07 | — | — | US | disclosed |
| EP-3885342-B1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-4405357-A1 | RIBONUCLEOSIDE ANALOGUES AGAINST -SARS-COV-2 | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2024-07-31 | — | — | EP | disclosed |
| US-7091214-B2 | Aryl substituted Imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-25 | — | — | US | disclosed |
| WO-2006027365-A1 | 2-SUBSTITUTED-6-TRIFLUOROMETHYL PURINE DERIVATIVES WITH ADENOSINE-A3 ANTAGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-03-16 | — | — | WO | disclosed |
| EP-1633750-A2 | SYNTHESIS OF 5-SUBSTITUTED 7-AZAINDOLES AND 7-AZAINDOLINES | Eisai Co., Ltd. (JP) | 2006-03-15 | — | — | EP | disclosed |
| US-20060052331-A1 | 2-Substituted-6-trifluoromethyl purine derivatives with adenosine-A3 antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-03-09 | — | — | US | disclosed |
| US-20060020004-A1 | Isoxazolidine compounds for treatment of bacterial infections | INFINITY PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | US | disclosed |
| WO-2006009907-A2 | ISOXAZOLIDINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | INFINITY PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2004078757-A2 | SYNTHESIS OF 5-SUBSTITUTED 7-AZAINDOLES AND 7-AZAIDONINES | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066365-A1 | Ribonucleoside Analogues Against -Sars-Cov-2 | SARS1, NSUN2, ACE2 | CA1 4843/4885CA2 3401/4885CYP1A2 1023/4885 |
| US-20060020004-A1 | Isoxazolidine compounds for treatment of bacterial infections | QDPR, NQO2, SQLE | CA1 4344/4885CA2 2200/4885CYP1A2 101/4885 |
| US-12186313-B2 | Pyridazinone compounds and their use as DAAO inhibitors | PNPO, DAO, DPYD | CA1 3015/4885CA2 3315/4885CYP1A2 8/4885 |
| US-20060052331-A1 | 2-Substituted-6-trifluoromethyl purine derivatives with adenosine-A3 antagonistic activity | ADORA3, ADORA2A, ADORA2B | CA1 4393/4885CA2 3286/4885CYP1A2 744/4885 |
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | TEAD1, TEAD2, TEAD3 | CA1 576/4885CA2 881/4885CYP1A2 62/4885 |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | GFER, MUC1, CTH | CA1 1918/4885CA2 2856/4885CYP1A2 2482/4885 |
| US-12512511-B2 | Solid electrolyte including polymer containing boron and fluorine structure, preparation method, and lithium ion battery including the same | SCN2B, VMP1, BRD9 | CA1 792/4885CA2 660/4885CYP1A2 3363/4885 |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | CA1 4409/4885CA2 4410/4885CYP1A2 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.